| Patient | Reported vent | Originally determined DS causality | Risk factors for hepatotoxicity not considered in original evaluation | DS causality determined on reevaluation |
| 55 yr female [20] | DS consumption of unknown daily dose for 6 months prior to symptom onset | WHO: Certain | BMI of 33, use of aspirin, preexisting hyperlipidemia | RUCAM: Unlikely |
| 48 yr female [20] | DS consumption of unknown daily dose for 9 months prior to symptom onset | WHO: Certain | BMI of 32, use of alpha adrenergic blocker for preexisting hypertension | RUCAM: Unlikely |
| 78 yr female [20] | DS consumption of unknown daily dose for 12 months prior to symptom onset | WHO: Certain | BMI of 27, use of aspirin, bisphosphonates, preexisting diabetes mellitus type II | RUCAM: Unlikely |
| 30 yr male [23] | DS consumption of unknown daily dose for 26 months prior to symptom onset | WHO: Certain | BMI of 33, preexisting Hepatitis E | RUCAM: Excluded |
| 44 yr female [21] | DS consumption of unknown daily dose for 6 months prior to symptom onset | WHO: certain RUCAM: Likely | BMI unknown, use of bupropion for 20 days reported. Case determined to be poorly documented. | RUCAM: Excluded |
| 39 yr female [22] | DS consumption of unknown daily dose for 6 months prior to symptom onset | Karch and Lasagna: Definite | BMI unknown, viral serology and imaging results not reported. Case determined to be poorly documented | RUCAM: Unlikely |
| 49 yr female [22] | DS consumption of unknown daily dose for 2 years prior to symptom onset | Karch and Lasagna: Conditional | BMI unknown, negative virology reported but no details provided, case determined to be poorly documented | RUCAM: Excluded |